Treating neuropathic pain and comorbid affective disorders: Preclinical and clinical evidence.

Pain practice : the official journal of World Institute of Pain 2024 Vol.24(7) p. 937-955

Coelho DRA, Gersten M, Jimenez AS, Fregni F, Cassano P, Vieira WF

관련 도메인

Abstract

[INTRODUCTION] Neuropathic pain (NP) significantly impacts quality of life and often coexists with affective disorders such as anxiety and depression. Addressing both NP and its psychiatric manifestations requires a comprehensive understanding of therapeutic options. This study aimed to review the main pharmacological and non-pharmacological treatments for NP and comorbid affective disorders to describe their mechanisms of action and how they are commonly used in clinical practice.

[METHODS] A review was conducted across five electronic databases, focusing on pharmacological and non-pharmacological treatments for NP and its associated affective disorders. The following combination of MeSH and title/abstract keywords were used: "neuropathic pain," "affective disorders," "depression," "anxiety," "treatment," and "therapy." Both animal and human studies were included to discuss the underlying therapeutic mechanisms of these interventions.

[RESULTS] Pharmacological interventions, including antidepressants, anticonvulsants, and opioids, modulate neural synaptic transmission to alleviate NP. Topical agents, such as capsaicin, lidocaine patches, and botulinum toxin A, offer localized relief by desensitizing pain pathways. Some of these drugs, especially antidepressants, also treat comorbid affective disorders. Non-pharmacological techniques, including repetitive transcranial magnetic stimulation, transcranial direct current stimulation, and photobiomodulation therapy, modulate cortical activity and have shown promise for NP and mood disorders.

[CONCLUSIONS] The interconnection between NP and comorbid affective disorders necessitates holistic therapeutic strategies. Some pharmacological treatments can be used for both conditions, and non-pharmacological interventions have emerged as promising complementary approaches. Future research should explore novel molecular pathways to enhance treatment options for these interrelated conditions.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 1
해부 neural synaptic scispacy 1
약물 antidepressants C0003289
Antidepressive Agents
scispacy 1
약물 capsaicin C0006931
capsaicin
scispacy 1
약물 botulinum toxin A C0006050
botulinum toxin type A
scispacy 1
약물 [INTRODUCTION] Neuropathic pain scispacy 1
약물 [CONCLUSIONS] scispacy 1
약물 lidocaine 리도카인 dict 1
질환 neuropathic pain C0027796
Neuralgia
scispacy 1
질환 comorbid affective disorders scispacy 1
질환 affective disorders C0525045
Mood Disorders
scispacy 1
질환 anxiety C0003467
Anxiety
scispacy 1
질환 depression C0011570
Mental Depression
scispacy 1
질환 psychiatric C0033873
Psychiatry Specialty
scispacy 1
질환 pain C0030193
Pain
scispacy 1
질환 mood disorders C0525045
Mood Disorders
scispacy 1
기타 human scispacy 1
기타 opioids scispacy 1
기타 cortical scispacy 1

MeSH Terms

Humans; Neuralgia; Mood Disorders; Animals; Antidepressive Agents; Comorbidity

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문